MediciNova to Participate in the B. Riley Neuroscience Conference
April 19, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova to Participate in the UBS Global Healthcare Virtual Conference
April 15, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
March 09, 2021 16:00 ET
|
MediciNova, Inc.
LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
March 08, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19
March 03, 2021 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Announces Closing of US$20 Million Private Placement Transaction
January 31, 2021 18:00 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Jan. 31, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan
January 18, 2021 18:00 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Jan. 18, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners
January 11, 2021 21:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS
December 29, 2020 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
MediciNova Added to the NASDAQ Biotechnology Index
December 15, 2020 06:30 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...